张 环, 赵志敬, 吴冠吉. 瑞舒伐他汀对不同血脂、C反应蛋白水平的不稳定型心绞痛患者颈动脉粥样硬化斑块的影响[J]. 心脏杂志, 2014, 26(3): 289-292.
    引用本文: 张 环, 赵志敬, 吴冠吉. 瑞舒伐他汀对不同血脂、C反应蛋白水平的不稳定型心绞痛患者颈动脉粥样硬化斑块的影响[J]. 心脏杂志, 2014, 26(3): 289-292.
    Effect of rosuvastatin calcium on carotid atherosclerotic plaques in unstable angina patients with different lipid and C-reactive protein levels[J]. Chinese Heart Journal, 2014, 26(3): 289-292.
    Citation: Effect of rosuvastatin calcium on carotid atherosclerotic plaques in unstable angina patients with different lipid and C-reactive protein levels[J]. Chinese Heart Journal, 2014, 26(3): 289-292.

    瑞舒伐他汀对不同血脂、C反应蛋白水平的不稳定型心绞痛患者颈动脉粥样硬化斑块的影响

    Effect of rosuvastatin calcium on carotid atherosclerotic plaques in unstable angina patients with different lipid and C-reactive protein levels

    • 摘要: 目的:探讨瑞舒伐他汀对不同血脂、C反应蛋白(CRP)水平的不稳定型心绞痛(UAP)患者颈动脉粥样硬化斑块的影响。方法:测定60例UAP患者低密度脂蛋白胆固醇(LDL-C)、超敏CRP(hsCRP)水平,并以LDL-C和hsCRP中位数水平为基础将受试者分为4组,所有入选患者口服瑞舒伐他汀10 mg/d,治疗12个月,分别于治疗前及治疗后3、6、9和12个月时测定三酰甘油(TG)、高密度脂蛋白胆固醇(HDL-C)、LDL-C、hsCRP水平,以及颈动脉中层厚度(IMT),并计算颈动脉斑块积分。结果:经瑞舒伐他治疗9个月,高LDL-C,高hsCRP组颈动脉斑块积分较治疗前下降(P<0.05),治疗12个月时下降更为显著(P<0.01);并且,高LDL-C低hsCRP组颈动脉斑块积分下降程度不如低LDL-C高hsCRP组明显;而低LDL-C低hsCRP组颈动脉斑块积分与治疗前相比无统计学意义。结论:hsCRP的检测可以作为是否进行他汀类药物治疗的参考指标,尤其是对于那些LDL-C降至正常水平的患者。

       

      Abstract: AIM:To observe the influence of shuxuening on high-sensitivity Creactive protein (hs-CRP) and matrix metalloproteinase-9 (MMP-9) in patients with unstable angina pectoris (UAP). METHODS: One hundred UAP patients were randomly divided into two groups: control group and therapy group, with 50 cases in each group. For 14 days, the control group was treated with the conventional treatment and the therapy group was treated with a combination of shuxuening (30 ml) with glucose injection (250 ml) once a day in addition to the conventional treatment. The levels of hs-CRP and MMP-9 were detected immediately, 12 h, 24 h, 48 h, 7 days and 14 days after hospitalization. RESULTS: hs-CRP level increased gradually, reached its peak at 24 h after hospitalization, and then decreased. MMP-9 level increased in the first 12 h and then decreased. Compared with those in the control group, levels of hs-CRP and MMP-9 decreased significantly at 12 h, 24 h, 48 h, 7 days and 14 days after hospitalization in the therapy group. CONCLUSION: Shuxuening can maintain the stability of atheromatous plaques by decreasing the levels of hs-CRP and MMP9 in UAP patients.

       

    /

    返回文章
    返回